To provide analytical solutions at Pivot Park Life Sciences Community, Oss, the Netherlands
Pivot Park 500MHz NMR Advance III Bruker spectrometer fitted with cryoprobe technology and sample-jet sample changer
Dutch contract research organisation Spinnovation Analytical has agreed with Pivot Park to supply analytical services at a newly established life sciences park in Oss, the Netherlands.
Pivot Park, located on the former Organon/Schering Plough/MSD research site is a centre for open innovation, where facilities, instruments and knowledge are made available to the pharmaceutical and biotech companies based on the site. It was officially opened in December 2012.
Spinnovation will further support the park’s research and productivity with its portfolio of analytical services that address the needs of both the small-molecule pharmaceutical and the biopharmaceutical industries.
The agreement will allow Spinnovation to expand and complement its technology platform, thanks to exclusive access to several high-end analytical instruments.
Spinnovation will cover the analytical needs of medicinal chemists focused on discovery programmes and pre-clinical development, as well as those of Contract Manufacturing Organisations (CMOs), by supporting Chemistry Manufacturing Control (CMC) activities. The extra NMR capacity provided by Spinnovation, including 400MHz and 500MHz with cryoprobe and high-throughput sample changers, will enable cost effective shared-access to routine NMR analyses. The advanced NMR screening methods that Spinnovation will provide will also eventually facilitate access to rapid ‘hit-validation assays’ as follow-ups to screening campaigns conducted at Pivot Park Screening Facility.
Mass spectrometry capabilities at the park will be increased by the addition of advanced Q-TOF applications, which support drug metabolite identification and biologics characterisation.
The advanced facilities available at Pivot Park will also help Spinnovation further strengthen and develop Spinnovation Biologics, a service offered to the European and US biopharmaceutical industry. Spinnovation Biologics supports upstream process development, including the profiling of cell culture media for the production of biotherapeutics using Spedia-NMR, troubleshooting issues in bioprocess with Spedia-Predict and performing profiling and characterisation of raw material, biologics and biosimilars.